Clavis Pharma to present at the Rodman & Renshaw Annual Healthcare Conference
Oslo, Norway, 8 September 2009
Clavis Pharma ASA (OSE: CLAVIS) has been invited to present at the Rodman & Renshaw Annual Healthcare Conference, New York, on Wednesday September 9, 2009. Geir Christian Melen, CEO, will present the company from 10:00 AM at The New York Palace Hotel, New York.
The presentation will be webcasted live and archived for 90 days on the Clavis Pharma website at www.clavispharma.com. To see the presentation click here: LIVE WEBCAST.
Geir Christian Melen will be available for one-on-one meetings during the Conference on September 9-11, 2009.
For further information or booking of one-on-one meetings, please contact:
Geir Christian Melen, CEO
Office : +47 24 11 09 65
Mobile : +47 91 30 29 65
E-mail : geir.christian.melen@clavispharma.com
Gunnar Manum, CFO
Office : +47 24 11 09 71
Mobile : +47 95 17 91 90
E-mail : gunnar.manum@clavispharma.com
About Clavis Pharma
Clavis Pharma ASA is an oncology focused pharmaceutical company using its proprietary Lipid Vector Technology (LVT) platform
to create New Chemical Entities (NCEs), by significantly improving already established drugs. The improvements are achieved
by chemically binding specific unsaturated lipids to existing, and well understood, approved pharmaceuticals. Data generated
suggests the resulting patentable NCEs offer improved efficacy and reduced side effects through enhanced pharmacokinetic properties,
greater tissue penetration and, in many cases, additional modes of action.
Clavis Pharma's objective is to develop its drug candidates until significant value has been created and proof of principle in man has been shown. For further clinical development and commercialisation of the products, Clavis Pharma will enter into strategic partnerships with established pharmaceutical or biotech companies. The company's product portfolio includes four new cancer drugs: Elacytarabine is in Clinical Phase II, Intravenous CP-4126 is in Clinical Phase II, Oral CP-4126 in Phase I, and CP-4200 is in preclinical development. Results indicate that these products have promising potential for several cancer indications within solid tumours and leukaemia.
The shares of Clavis Pharma ASA are listed on the Oslo Stock Exchange (ticker: CLAVIS). Additional information on Clavis Pharma can be found at: http://www.clavispharma.com/.